Absorption and Digestion Kinetics of Human Metabolites
- Conditions
- Postprandial Inflammation
- Registration Number
- NCT05017428
- Lead Sponsor
- University of California, Davis
- Brief Summary
The purpose of this pilot study is to evaluate the effects oral supplementation with four human metabolites (spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide(OEA)) at varying doses on the circulating blood levels of these metabolites as well as their immediate effects on plasma functionality and postprandial inflammation. 5 young healthy subjects will participate in a four armed study consisting of a Placebo arm and a Low, Medium, and High Dose arm. Subjects will be given a standardized breakfast along with supplementation with either an escalating dose (Low: 1x, Medium: 2x, High: 3x) of a combination of spermidine, nicotinamide, PEA and OEA or a placebo control and a time course of their blood plasma will be collected after supplementation. Plasma samples will be assessed for their concentration of spermidine, nicotinamide, PEA, and OEA as well as their experimental and clinical functionalities including their anti-inflammatory, antioxidant, and cholesterol efflux abilities on primary human macrophage.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 5
- Age: 20-40 years old to constitute a young study population
- BMI: 19-27 kg/m2 to constitute a normal/healthy weight population
- Weight: 133lbs or more
- Subjects must be willing and able to consume a standardized breakfast bar containing cashews and dates (Larabar).
- Subjects must be willing to consume oral dietary supplement versions of spermidine, 1-methlynicotinamide, palmitoylethanolamide, and oleoylethanolamide.
- Subjects must be willing and able to undergo blood draws at the UC Davis Ragle Nutrition Center at 0, 1, 2, and 4 hours after supplementation with spermidine, niacinamide, palmitoylethanolamide, and oleoylethanolamide.
- Smoker
- Anemia
- Documented chronic diseases including diabetes, thyroid disease, metabolic syndrome, cancer, autoimmune diseases, or previous cardiovascular events
- Any inflammatory bowel disease including IBS, Crohn's Disease, Celiac Disease
- Any allergy or sensitivity to wheat, gluten, or soy products
- Consumption of >1 alcoholic drink/day
- Current consumption of any probiotic, prebiotic, or dietary supplements
- Extreme dietary or exercise patterns
- Recent weight fluctuations (greater than 10% in the last six months)
- Regular use of over-the-counter allergy or pain medications (>1/week)
- Taking prescription lipid medications (e.g. statins) or other supplements known to alter lipoprotein metabolism such as isoflavones.
- Use of any form of hormonal birth control including oral contraception pills, hormonal IUDs or rings, or hormonal birth control patches
- Illness such as flu or cold of any kind within the last two weeks
- Allergy to components of standardized breakfast bar (cashew/dates)
- Changes to any of the above during the study period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Circulating Plasma Levels of Metabolites 1, 2, and 4 hours after ingestion Quantitative plasma concentrations of spermidine, nicotinamide, pamitoylethanolamide, and oleoylethanolamide (in nmol/L).
- Secondary Outcome Measures
Name Time Method Anti-inflammatory capacity of plasma 1, 2, and 4 hours after ingestion Ex vivo assessment of the effects of subject plasma on the secretion of pro-inflammatory cytokine TNF-alpha (pg/mL) by primary human macrophage
Trial Locations
- Locations (1)
University of California Davis
🇺🇸Davis, California, United States
University of California Davis🇺🇸Davis, California, United States